<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135510</url>
  </required_header>
  <id_info>
    <org_study_id>2011/366</org_study_id>
    <nct_id>NCT02135510</nct_id>
  </id_info>
  <brief_title>MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy</brief_title>
  <acronym>MEDEA</acronym>
  <official_title>MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Noordwest Ziekenhuisgroep - Alkmaar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tergooiziekenhuizen locatie Hilversum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Amstelland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Noordwest Ziekenhuisgroep - Den Helder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and
      palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard
      to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by
      non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy
      (MEC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>24 to 160 hours</time_frame>
    <description>Primary efficacy endpoint: the proportion of patients reporting complete response during the overall 24 to 160 hours after initiation of the first cycle of moderately emetogenic chemotherapeutic (MEC). Complete response is defined as no vomiting and nausea and no use of rescue medication. A diary will be used to document the date and time of any emetic episodes and use of rescue medication, as well as daily nausea ratings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tolerability</measure>
    <time_frame>24 to 160 hours</time_frame>
    <description>Primary tolerability endpoint: the proportion of patients with minimal or no antiemetic therapy-related side effects according to the Dexamethasone Symptom Questionnaire (DSQ) questionnaire, the Abnormal Involuntary Movement Scale (AIMS) and Aprepitant questionnaire during the first cycle of moderately emetogenic chemotherapeutic (MEC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cost-effectiveness</measure>
    <time_frame>24 to 160 hours</time_frame>
    <description>Primary cost-effectiveness endpoint: total antiemetic medication costs per treatment regimen during the first cycle of Moderately Emetogenic Chemotherapy (MEC). A diary will be used to document the use of antiemetics and rescue medication. Total medication costs will be calculated from this.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethason</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>palonosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <arm_group_label>metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethason</intervention_name>
    <arm_group_label>dexamethason</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron</intervention_name>
    <arm_group_label>palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been diagnosed with histologically or cytologically confirmed solid cancer

          -  Starting with first cycle of chemotherapy of moderate emetogenic risk, which does not
             include a combination of anthracycline plus cyclophosphamide

          -  Age ≥ 18

          -  WHO ≤ 1

          -  Patient is able to understand and speak Dutch

        Exclusion Criteria:

          -  Patient with nausea and/or vomiting in 48 hours before start of chemotherapy treatment

          -  Patient submitted to concomitant radiotherapy or submitted to radiotherapy 15 days
             before start of chemotherapy or planned to receive radiotherapy during 8 days after
             administration of chemotherapy

          -  Patient with concomitant severe comorbidy, such as: o Intestinal obstruction o Active
             peptic ulcer o Hypercalcemia o Uncontrolled diabetes mellitus o Pheochromocytoma o
             Tardive dyskinesia o Epilepsia o Active infective diseases o Brain - or leptomeningeal
             metastases o Psychiatrical disorders o Parkinsonism

          -  Current use of corticosteroids (similar to prednisone ≥ 10 milligrams per day)

          -  Current alcohol abuse

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gemini Ziekenhuis</name>
      <address>
        <city>Den Helder</city>
        <state>Noord Holland</state>
        <zip>1782 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.C.S. Tromp-van Driel</last_name>
      <phone>(0223) 69 69 69</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <state>Noord Holland</state>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.P. van den Berg</last_name>
      <phone>088 753 17 53</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Vrijaldenhoven</last_name>
      <phone>(072) 548 2870</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Amstelland</name>
      <address>
        <city>Amstelveen</city>
        <state>Noord-Holland</state>
        <zip>1186 AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. van Zweeden</last_name>
      <phone>(020) 755 7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waterland Ziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <state>Noord-Holland</state>
        <zip>1441 RN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J Brakenhoff</last_name>
      <phone>0299 457 457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>De Heel - Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <state>Noord-Holland</state>
        <zip>1502 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. van Bochove</last_name>
      <phone>(075) 650 29 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T van Voorthuizen</last_name>
      <phone>+31(0)88 005 8888</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>H.M.W. Verheul</investigator_full_name>
    <investigator_title>Head Department Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

